Blepharospasm Patient Survey for Patients With Blepharospasm
Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm
1 other identifier
observational
124
1 country
5
Brief Summary
The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2012
Shorter than P25 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedFirst Submitted
Initial submission to the registry
September 12, 2012
CompletedFirst Posted
Study publicly available on registry
September 17, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2013
CompletedOctober 28, 2022
April 1, 2014
7 months
September 12, 2012
October 26, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Botulinum Toxin Treatment Information
The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected: (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS)
This is a single, structured interview about experiences with Botulinum Toxins
Study Arms (1)
Blepharospasm Survey Group
Interventions
Eligibility Criteria
Patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA treatment.
You may qualify if:
- Male or female subject aged \> 18 years and \< 81 years
- Documented clinical diagnosis of blepharospasm
- Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA
You may not qualify if:
- Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Merz Pharmaceuticals GmbHlead
- Merz North America, Inc.collaborator
Study Sites (5)
Merz Investigative Site #0007
Fountain Valley, California, 92708, United States
Merz Investigative Site # 0002
Sarasota, Florida, 34239, United States
Merz Investigative Site # 0001
Boston, Massachusetts, 02111, United States
Merz Investigative Site #003
Durham, North Carolina, 27710, United States
Merz Investigative Site # 0006
Columbus, Ohio, 43215, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Micki Seoane
Merz Pharmaceutical, LLC
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 12, 2012
First Posted
September 17, 2012
Study Start
September 1, 2012
Primary Completion
April 1, 2013
Study Completion
April 1, 2013
Last Updated
October 28, 2022
Record last verified: 2014-04